Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study
Year: 2020
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Infectious Diseases
Authors: Elliott Geoffrey Playford, Trent Munro, Stephen M Mahler, Suzanne Elliott, Michael Gerometta, Kym L Hoger, Martina L Jones, Paul Griffin, Kathleen D Lynch, Heidi Carroll, Debra El Saadi, Margaret E Gilmour, Benjamin Hughes, Karen Hughes, Edwin Huang, Christopher de Bakker, Reuben Klein, Mark G Scher, Ina L Smith, Lin-Fa Wang, Stephen B Lambert, Dimiter S Dimitrov, Peter P Gray, Christopher C Broder
Institutions: The University of Queensland, Princess Alexandra Hospital, Q-Pharm, QIMR Berghofer Medical Research Institute, Queensland Health, Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Henry M. Jackson Foundation, Duke-NUS Medical School, University of Pittsburgh, Uniformed Services University of the Health Sciences
Language: English
Topic: Virology and Viral Diseases
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3003639174